Abstract
Type 1 interferonopathies encompass a group of autoinflammatory diseases in which overactivation of the type I interferon pathway is the keystone. In this article, we describe the elaboration and clinical aspects of the interferon signature (or score) at the level of these rare monogenic diseases, but also in more common rheumatologic conditions, discuss its potential implications for therapeutic options for patients, and open future perspectives of transcriptomic analysis in immunoinflammatory diseases.